■ Methods
The National Institute of Health's National Library of Medicine MEDLINE electronic database was searched from January 1966 through March 2007 for the key term "pressure ulcer risk assessment" combined with the search terms: (1) controlled study, (2) validity, (3) positive predictive value, (4) sensitivity, (5) negative predictive value, and (6) specificity. The search was expanded to include relevant derivative unique references and abstracts. Studies on simulated case studies were excluded from the review to optimize clinical relevance and avoid their methodologic issues. 6 Facts were verified by contacting authors or websites identified using the internet-based Google and Yahoo search engines. Reviews and secondary sources were used when access to the primary source was unavailable. This was not a systematic review, but a synthesis of literature, summarizing results to focus readers on the best available evidence of PURAS validity and reliability for their settings and patients.
PURAS quality was measured as reliability and criterionrelated predictive validity. 7 Predictive validity criteria for PU risk assessment screening include sensitivity, specificity, predictive value of a positive test (PVP), and predictive value of a negative test (PVN). 1 Unlike diagnostic tools, which require maximum sensitivity and specificity (>80%) to avoid dire consequences of misdiagnosis, such high levels of validity are not expected for PU risk screening, which also may function to guide PU prevention interventions, improving patient outcomes, and lowering apparent criterionrelated validity in the process. Sensitivity and specificity represent how accurately the scale reflected all patients' final PU development (PU+) or PU-free (PU−) status and may help medical management evaluate the consistency with which a PURAS gauges or guides patient risk management. Predictive value of a positive or negative test represents the scale's capacity to predict the PU+ or PU− outcome and may help bedside clinicians plan risk management for an individual patient. Percent correct is an overall measure of scale accuracy in predicting both PU+ and PU− patient outcomes reported during the interval studied. Operational definitions 8 of the criteria used in this summary are presented in Box 1 and Box 2.
Question 1: What are the most valid, reliable scales for assessing pressure ulcer risk?
Results of the literature search are presented in Table 1 . Unless random selection is specified in the first column of Table 1 , convenience samples were used. The evidence summarized in Table 2 demonstrates that the Braden, then Norton and Waterlow PU risk assessment scales have the strongest evidence supporting their validity and reliability, reflected in respective predictive odds ratios 9 (likelihood of a patient with a total score at or beneath the cut point developing a PU) of 4.08, 2.16, and 2.05 (P < .05), surpassing nurses' clinical judgment (odds ratio 1.69; P >.05). The act of assessing PU risk does not reduce PU incidence, but it does increase the intensity and effectiveness of PU prevention interventions. 
(text continued on p 378)
Reliability is the repeatability of risk ratings by the same (intrarater) or different (interrater) wound care professionals expressed as either percent agreement 100 × (number of rater agreements) / (number of rater agreements + disagreements) or correlations between ratings of PU risk for the same set of subjects.
Sensitivity answers the question, "What percent of patients who actually developed a PU were classified as 'at PU risk' by the scale?" From Table 1 , it is calculated as 100 × (a) / (a + c). Scales with low sensitivity underscreened the PUs that developed. They screen an excess of "false negative" PUs identified, to the extent that c in Table 1 becomes larger than a.
Specificity answers the question, "What percent of patients remaining PU-free did the scale accurately rate as 'not at PU risk'?" From Table 1 , it is calculated as 100
Scales with low specificity overscreened PU development, with excess "false positive" PUs identified.
Predictive value of a positive (PVP) rating is the percentage of subjects designated "at PU risk" who develop a PU. It answers the question, "How accurately does the PURAS prospectively predict whether a subject you are rating now will develop a PU?" It is calculated from Table 1 as 100 × (a) / (a + b). A low value indicates that that you may overpredict the likelihood of a PU in the subject you are screening.
Predictive value of a negative (PVN) rating answers the question, "How accurately does the PURAS prospectively predict which patients will not develop a PU?" It is calculated from Table 1 as 100 × (d) / (c + d). A low value indicates users may miss patients truly at risk because the test is prone to "false negative" PU predictions. [16] Prospective cohort 9, 29 [20] Stage I-IV Prospective study 30 [16] Prospective study 31 [16] Prospective study 32 all PU [16] Open PU (only Stage II) [16] Review 26 [17] [17] Prospective study 33 [18] Prevalence survey follow-up 34 PU+ all PU stages [16] PU− all PU stages [16] PU− all PU stages [19] PU− PU stage [16] Prospective study 36 [16] Retrospective chart review 37 Braden Scale [16]
⎟⎟
Braden Scale [16] Modified Braden [8] Prospective study 38 [16] Prospective study 39 [16] [18] Prospective study 15 [18] [19] Prospective study 39 [16] [19] Prospective cohort study 40, 41 Braden Q-7 subscales [16] Braden Q-3 subscales [7] Prospective study 41, 42 NRAS All 7 subscales [16] Best 3 subscales [7] Fragment Scale Prospective cohort [4] 9,43
Norton Scale Survey 44 [12] Prospective study 45 [12] Review of 2 studies 48 Norton Waterlow Prospective concurrent 54 Braden [15] Pre-PU Braden [16] Pre-PU Braden [18] Pre-PU Prospective study 55 Braden [18] Pre-PU Braden [19] Pre-PU Prospective concurrent 56 Braden [16] Gosnell [16] Norton [16] Waterlow [16] Prospective concurrent 16 age, diastolic blood pressure, fever Prospective study [18] 11
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Setting
Clinical Evidence of Reliability and Validity of Pressure
Prospective study [18] 39
Norton Scale
Descriptive longitudinal study 67 Norton when the nurses who completed the scale were directly engaged in care of the patient they rated. 10 Cut Points. It is also essential to determine the cut point (score) that best identifies patients at significant risk of developing a PU. Cut points are usually determined by balancing sensitivity and specificity as the inflection point on a Receiver Operating Curve with 1-specificity as the abscissa and sensitivity as the ordinate. Cut points are typically higher in extended care, 11 for example 18 on the Braden Scale instead of 16, which is normally used in more acute care settings. They also vary with patient acuity. On the first and second days after surgery the cut point for predictive validity briefly drops to 13 or 14 during which Braden Scale predictive validity is optimal. 12 Inconsistent use of <, >, ≥ or ≤ in the literature signals a need to clarify precise cut points, such as the proposed Braden Scale categories: 13 "at risk" = 15-18; "moderate risk" = 13-14; "high risk" = 10-12; "very high risk" = 9 or below. This may help users manage PU risk variations as a continuum rather than responding to patient risk as a binary "all-or-none" variable.
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Setting
What patients benefit from administration of a PURAS? Evidence supports use of an appropriately validated PURAS in all patients of questionable clinical condition of any age, gender, nationality, or level of skin pigmentation admitted to a hospital's surgical, intensive care, orthopedic, cardiovascular, medical or step-down units, home care, hospice, or a variety of extended care facilities. No evidence supports assessing PU risk on individuals in good clinical condition, 13 as evidenced by low preoperative and postoperative recovery day 5 validity of the Braden Scale. 12 Though much of the validation literature addressed only ulcer-free patients, those with a PU also may benefit from PU prevention interventions guided by regular PU risk assessment. 5 When should PU risk be assessed? The optimal timing for assessment of PU risk varies across settings. Usually the first PU risk assessment is performed on or within 72 hours after admission. Home care patients of questionable clinical status are assessed on admission, then weekly or biweekly until the patient is discharged from care. 14 In long-term care and some hospital settings, most PUs develop in 2-4 weeks following admission and PURAS validity measures peak just before PU onset. 11, 15, 16 Predictive validity is optimized by continued assessment in nursing home populations. In hospitals, the 50% incidence of preoperative PU skin damage 17 suggests preoperative PU preventive interventions in addition to those aimed at reducing the 12.5% PU incidence while the patient is on the operating room table. Assessing PU risk factors can help intensive care, recovery room, and step-down unit staffs focus resources on efforts that help avoid the long-term devastation of a PU.
Question 3: Does use of a PURAS guide preventive interventions?
A PURAS performs 2 basic functions: (a) identifying patients at risk of developing a PU and (b) guiding preventive interventions. Existing evidence demonstrates that 3 PURAS provide a valid instrument for screening and predicting PU risk. Research also supports a second role of PURAS as a guide to implementing or focusing PU prevention protocols of care to reduce PU incidence. [18] [19] [20] Assessing patient risk of developing a PU does little good for the patient or institution unless information from that assessment is linked to effective preventive interventions. Limited evidence exists suggesting that use of a validated PURAS alerts professionals to risk and guides subsequent interventions. For example, a Braden Mobility Scale score of 1, 2, or 3 21 may guide that patient's PU prevention protocol to include appropriate pressure redistribution. Focusing on the elements of high PU risk for each patient saves time, money, and resources for other aspects of care, while improving clinical outcomes. 18, 20, 22 ■ Discussion and Conclusions PU prediction tends to overpredict risk. The US Preventive Services Task Force has developed criteria for evaluating screening test appropriateness. 23 Leading criteria are; (1) treatment evidence-based efficacy and safety, (2) burden of the condition (mortality, morbidity, discomfort), and (3) quality of the test (accuracy, safety, acceptability, simplicity, and cost). Among the PURAS reviewed here, the Braden, Norton, and Waterlow Scales have evidence of accuracy and appear to meet all 5 criteria in several settings, with overprediction of a PU as the weakest metric of predictive validity. The consequences of this overprediction are that a patient may receive needless PU preventive care. It would be far more serious if a PURAS underpredicted PU likelihood, failing to direct PU preventive care where it is needed. The act of assessing or acknowledging PU risk, itself, may reduce the likelihood of pressure ulceration, 24, 25 thus accentuating the "overprediction" effect. As staff and/or patients focus on alleviating risk factors identified while assessing patient risk, they improve PU prevention strategies. 15, 20 While this may seem a shortcoming of risk assessment scales, 26 it highlights their capacity to reduce PU incidence, paradoxically contributing to their tendency to overpredict risk. Achieving a significant difference between PURAS-predicted and the actual rate of PU occurrence in a clinical unit may be a meaningful measure of quality of care.
The overprediction of PUs may also represent a sampling artifact cause by short hospital stays. For example very ill patients managed in a hospice setting may expire before developing PUs predicted by the scale. This artifact diminishes when the analysis excludes patients who died before the study ended. 27 These findings highlight the importance of patient comorbid factors, length of stay, and study duration when evaluating instruments that measure PU risk.
Limitations
This review did not address the growing body of research seeking to more precisely identify means to measure individual risk factors or subscale analyses such as albumin measurement and the Waterlow Scale. 28 A recent systematic review 9 covered a greater variety of databases and more references than this MEDLINE search found. The authors found 3 controlled studies, 2 on nonvalidated modifications of the Norton Scale examining effects of using a PURAS on PU incidence. None supported the conclusion that using a PURAS per se affects PU incidence. Nevertheless, controlled studies are needed to test this hypothesis before clear conclusions can be drawn.
An additional limitation of the literature reviewed was lack of a clear, unified definition of PURAS quality. Initially the literature search included controlled studies of convenience or ease of use or implementation, but I found no reliable or valid metrics for these aspects of PURAS clinical use. This could be an important area for further research, because tools that are easier or more convenient to implement and use are more likely to be used by busy clinical staff. This research was conducted and written without support or funding from any commercial organization.
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